Important adverse events to be evaluated in antidepressant trials and meta-analyses in depression: a large international preference study including patients and healthcare professionals
Sign Up to like & getrecommendations! Published in 2022 at "Evidence-Based Mental Health"
DOI: 10.1136/ebmental-2021-300418
Abstract: Background Non-serious adverse events (NSAEs) should be captured and reported because they can have a significant negative impact on patients and treatment adherence. However, the reporting of NSAEs in randomised controlled trials (RCTs) is limited.… read more here.
Keywords: important adverse; antidepressant trials; meta analyses; important nsaes ... See more keywords
Increase in pharmacodynamic tolerance after repeated antidepressant trials in treatment-responsive bipolar I depressed subjects: An exploratory study.
Sign Up to like & getrecommendations! Published in 2018 at "Psychiatria polska"
DOI: 10.12740/pp/98961
Abstract: OBJECTIVES This study examined the presence of increased pharmacodynamic tolerance with reduced effectiveness following repeated antidepressant trials over the course of the affective illness in subjects with treatment-responsive bipolar II depression. METHODS Data were derived… read more here.
Keywords: repeated antidepressant; antidepressant trials; treatment responsive; pharmacodynamic tolerance ... See more keywords
Raising Placebo Efficacy in Antidepressant Trials Across Decades Explained by Small-Study Effects: A Meta-Reanalysis
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Psychiatry"
DOI: 10.3389/fpsyt.2020.00633
Abstract: Background Recent meta-analyses reported placebo response rate in antidepressant trials to be stable since the 1970s. These meta-analyses however were limited in considering only linear time trends, assessed trial-level covariates based on single-model hypothesis testing… read more here.
Keywords: placebo efficacy; small study; time trends; study effects ... See more keywords